axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
ormp
- Creatore Discussione axelvento
- Data di inizio
playars
lotto players
- Registrato
- 11/4/08
- Messaggi
- 8.306
- Punti reazioni
- 174
minimo vale il doppio di $10
Oramed Pharmaceuticals announced that it has entered into definitive agreements with investors to purchase an aggregate of 1.58 mln shares of common stock at a price of $10.00/share in a registered direct offering
Oramed Pharmaceuticals announced that it has entered into definitive agreements with investors to purchase an aggregate of 1.58 mln shares of common stock at a price of $10.00/share in a registered direct offering
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
news_
Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (Oramed - Home), a developer of oral drug delivery systems, announced today that it has received Notices of Allowance from the Israel and Australian Patent Offices. The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept of the company's technology for the oral delivery of drugs and vaccines currently delivered via injection. The allowance in Israel marks the second from the Israel Patent Office in the past 30 days. Additionally, this is Oramed's second Australian patent allowance, following the grant of a different patent in May 2012. The patent has also been approved in Japan, China, Russia, and New Zealand.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (Oramed - Home), a developer of oral drug delivery systems, announced today that it has received Notices of Allowance from the Israel and Australian Patent Offices. The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept of the company's technology for the oral delivery of drugs and vaccines currently delivered via injection. The allowance in Israel marks the second from the Israel Patent Office in the past 30 days. Additionally, this is Oramed's second Australian patent allowance, following the grant of a different patent in May 2012. The patent has also been approved in Japan, China, Russia, and New Zealand.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
axelvento
dCellVax
- Registrato
- 21/12/04
- Messaggi
- 16.246
- Punti reazioni
- 419
